Cytek Biosciences, Inc. (NasdaqGS:CTKB) is looking for M&A. Patrik Jeanmonod, Chief Financial Officer said, "We will continue to invest in our core business as it relates to new project and innovation while remaining opportunistic in the M&A environment and focusing on growth in all key areas".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.92 USD | -0.67% | -4.05% | -35.09% |
Mar. 20 | Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing | MT |
Mar. 19 | Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.09% | 780M | |
+2.64% | 207B | |
+1.80% | 175B | |
+8.59% | 132B | |
+16.47% | 99.1B | |
-3.42% | 60.89B | |
+12.71% | 52.04B | |
-6.61% | 45.48B | |
-4.53% | 38.81B | |
+9.27% | 38.77B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences Seeks M&A